Prevalence of urinary colonization by extended spectrum-beta-lactamase Enterobacteriaceae among catheterised inpatients in Italian long term care facilities

ARNOLDO, L, et al.

Abstract
Long Term Care Facilities (LTCFs) play a key role in guaranteeing care to patients in developed countries. Many patients, mostly elderly, access LTCFs at some time in their lives, and their healthcare pathways often require them to move back and forth between hospital and outpatient settings. These patterns bring about new challenges regarding infection control, especially healthcare associated infections.

Reference
ARNOLDO, L, et al. Prevalence of urinary colonization by extended spectrum-beta-lactamase Enterobacteriaceae among catheterised inpatients in Italian long term care facilities. *BMC Infectious Diseases*, 2013, vol. 6, no. 13, p. 124

DOI : 10.1186/1471-2334-13-124
PMID : 23497323

Available at:
http://archive-ouverte.unige.ch/unige:42972

Disclaimer: layout of this document may differ from the published version.
Prevalence of urinary colonization by extended spectrum-beta-lactamase Enterobacteriaceae among catheterised inpatients in Italian long term care facilities

Luca Arnoldo, Roberta Migliavacca, Laura Regattini, Annabile Raglio, Laura Pagani, Elisabetta Nucleo, Melissa Spalla, Francesca Vallati, Antonella Agodi, Adriana Mosca, Carla Zotti, Stefano Tardivo, Ines Bianco, Adele Rulli, Paola Guidali, Pietro Panetta, Carlo Pasini, Mino Pedroni and Silvio Brusaferro

Abstract

Background: Long Term Care Facilities (LTCFs) play a key role in guaranteeing care to patients in developed countries. Many patients, mostly elderly, access LTCFs at some time in their lives, and their healthcare pathways often require them to move back and forth between hospital and outpatient settings. These patterns bring about new challenges regarding infection control, especially healthcare-associated infections.

Methods: A point-prevalence study was conducted in 23 Italian LTCFs, to identify colonization in patients with urinary catheter (>24 hours). Species identification, susceptibility tests and extended spectrum beta-lactamase (ESBL) production screenings were performed using Vitek 2 System. Enterobacteria identified by Vitek 2 System as ESBL-producers or suspected AmpC hyperproducers on the basis of cefepime resistance, were sent to a research laboratory where they underwent a double-disk synergy test. Finally, ESBL-producers were screened for bla resistance genes by PCR assay.

Results: 211 patients with catheter were screened. 185 out of 211 patients showed positive samples for the presence of Enterobacteriaceae. 1/14 of these 185 patients were colonized by extended spectrum cephalosporins resistant microorganisms. We identified a total of 257 Gram negative pathogens, of which 51.8% (133/257) were extended-spectrum cephalosporin-resistant. 7 out of 133 cephalosporin not susceptible strains proved to be AmpC-type beta-lactamases and 125/133 ESBL-producers; 43 out of 257 (16.7%) E. coli, 37/257 (14.4%) P. mirabilis, 20/257 (7.8%), P. stuartii, 14/257 (5.4%) M. morganii, 7/257 (2.7%), K. pneumoniae, 4/257 (1.6%) C. koseri proved to be overall ESBL-producers by double-disk synergy test. Third and fourth generation cephalosporin resistant P. mirabilis, P. stuartii and M. morganii strains mainly harboured a blaTEM gene (95.9%), while 89.1% of E. coli were positive for the blaCTX-M determinant by PCR and sequencing. Patients with decubitus had a higher risk of colonization by at least one resistant isolate (p < 0.01). Samples of patients undergoing antibiotic therapy and patients with decubitus showed a higher risk (p < 0.05) of colonization by beta-lactam resistant microorganisms.

Conclusions: These data confirm the presence of high percentages of ESBL-positive Enterobacteria in Italian LTCFs and the predominance ofCTX-M type ESBL in E. coli. The alarming presence of ESBL-producing Enterobacteriaceae in Italian LTCFs can seriously compromise the effectiveness of antibiotic therapy facilities (LTCFs). Antimicrobial resistance.
Background
Long Term Care Facilities (LTCFs) play a key role in guaranteeing care to patients in developed countries. Many patients, mostly elderly, access LTCFs at some time in their lives, and their healthcare pathways often require them to move back and forth between hospital and outpatient settings [1].

These patterns bring about new challenges regarding infection control, especially healthcare associated infections (HAI). This is also true considering that LTCFs differ from acute intensive care settings in clinical approaches, models, organization of care, and quantity and quality of human resources. Nevertheless, they usually make a limited use of diagnostic and microbiological tests [2] and therefore, laboratory surveillance suffers from the lack of this kind of approach in prescribing specific tests.

Antibiotic resistance is consistently present in these settings, and this has a critical impact also because patients frequently move back and forth within and between other healthcare organizations [3-5].

A better knowledge of the epidemiology of antibiotic resistance patterns in LTCFs is necessary, because the spread of Extended Spectrum Beta-Lactamases (ESBL) and recently of Beta-Lactamases (BL) with carbapenemase activity (e.g. K. pneumoniae KPC producer) [6], has emerged as a major source of antibiotic resistance in gram-negative pathogens, and this is one of the most important causes of antibiotic therapy failure [7-9]. The emergence of ESBL-producers has important clinical and therapeutic implications because these microorganisms are responsible for both hospital and community acquired infections [10,11].

Point prevalence surveys are useful tools to conduct an initial study of the spread of resistant microorganisms in a population at risk such as the elderly, to understand the burden of the problem, and to define a benchmark of resistance genes to control their development.

ESBL acquisition is associated with the following risk factors: presence of decubitus, presence of a gastrostomy tube, poor functional condition, prior use of ciprofloxacin, prior use of trimethoprim-sulfamethoxazole [12,13]. These clinical risk factors refer to a specific geriatric population that is largely predominant in LTCFs.

Although ESBL-producers are a major concern in the clinical field and their presence in different Italian settings has been reported, nationwide data on their prevalence in LTCF residents are not available [14].

The aim of this study is to detect the circulation of BL-producing Enterobacteriaceae, particularly ESBL, in Italian LTCFs.

Methods
We conducted a point prevalence study in 23 Italian LTCFs at the end of 2006, looking for colonization in patients with urinary tract catheters (>24 hours) at the time of the study. In each LTCF, the point prevalence survey began and was completed within an index day. Eight contact centres (CCs) were set up in different parts of the country as reference centres for the local LTCFs (involved on a voluntary basis); each CC had to guarantee:

- a minimum of 9 patients
- filled-in patient data forms
- presence of laboratory with VITEK 2 technology
- possibility of the laboratory to isolate strain and freeze it for later use.

Patients joined the study on a voluntary basis after signing an informed consent statement. Patient data were used anonymously. At the time of the study, there was no legal obligation (DM 15/07/1997 and DM 12/05/2006) to obtain the approval of an Ethic Committee prior to conducting an observational (non experimental) studies.

Urine samples, collected by nursing staff directly from the catheter valve, were sent to CC laboratories for culture and species identification of the Enterobacteria present in all samples (by inoculation of 0,001 mL on McConkey agar, incubation at 35°C for 24 h). Species identification, susceptibility tests and ESBL-production screenings were carried out using 21341-GN and 22088-AST-N041 cards, Vitek 2 System (Bio-Mérieux). Enterobacteria identified as ESBL-producers by Vitek 2 System or as suspected AmpC hyperproducers due to their cephalosporin resistance, were stocked and sent to the research laboratory of the University of Pavia, where the microorganisms were subjected to both the double-disk synergy test using piperacillin-tazobactam (TZP) and cefotaxime (CTX), cefepime (FEP), ceftazidime (CAZ) and aztreonam (ATM), and to the combo confirmatory test according to CLSI recommendations [15].

All ESBL-producers were screened for bla_shv, bla_tem, bla_CTX-M and bla_OXA resistance genes by PCR assay, using primers as summarized in Table 1. Control organisms included strains of E. coli containing either bla_tem, bla_SHV, bla_OXA-4, bla_CTX-M-15 or bla_CTX-M-9 genes.

Given the previously reported description of CMY-16 in P. mirabilis from northern Italy [21], P. mirabilis clinical isolates were also screened for the presence of the blacMY-16 gene, using specific primers CMY-Exp_Fw GCTCTAGACATAATGATGAAATCGTTATGCTGGMY-Exp_Rev CGGGATCTTTATGACAGCTTTTCAAG AATG (1165 bp amplicon size).

A multiplex-PCR protocol was used to identify family-specific AmpC genes responsible for AmpC BL expression in organisms with or without a chromosomal AmpC BL gene [22]. Analytical isoelectric focusing (IEF) of crude cell extracts, visualization of BL bands by nitrocefin (gels were electrophoresed at 11 to 14 W for 90 min and BL revealed with 0.5 mM Nitrocefin) and detection of their
Table 1 Primers used for the detection of the presence of different beta lactamases genes by PCR

| Amplicon | Primer sequence (5’ to 3’) | Size (bp) |
|----------|----------------------------|-----------|
| blaSHV   | GCCCCGGTTATCTTATGTGCGCC   | 900 [16]  |
|          | TTTTCCGAGCCGCCGGCCAGTCGA |           |
| blaTEM   | ATAAAATTCTGAAGACGAGA      | 862 [17]  |
|          | ATAGAGTAAGCCTGTCGAGCAG    |           |
| blaCTX1  | ATGTGCGGACATGCAATGCGTA   | 593 [18]  |
|          | TGGTGTCATTTGACCAAAGCAG    |           |
| blaCTX1 M3/5’+3’ | GTTACAGTGGAGAGAGGAGCAG   | 1000 [18] |
|          | AACGGAAGTTTGCCCATT        |           |
| blaCTX1 M5’+3’ | ATGGTCTCATGACAGAAGAGTGCA | 835 [19]  |
|          | CTTTCGGCAGGTTTCTTCTC     |           |
| blaOXA1  | ACA CAA TAC ATA TCA ACT TCG C | 813 [20] |
|          | AGT GTG TTT AGA ATG GTG ATC |           |

activity by a substrate overlaying procedure, were performed as described.

Known producers of different BL (i.e., TEM-1, TEM-2, TEM-7, TEM-8, TEM-9, TEM-12, SHV-1, SHV-2 and SHV-5) were used as controls.

PCR amplicons of blaTEM, blaSHV, blaOXA, blaCTX1 genes were purified using the kit Quantum Prep PCR Kleen Spin Columns (BioRad) and subjected to direct sequencing. PCR products were sequenced on both strands with Applied Biosystems sequencers.

The nucleotide sequences were analysed according to the BLAST program.

For each patient, a standardized form was filled in; it included variables related to reported risk factors for HAI in LTCTFs [23]:

- patient data (gender, age, residence prior to admission to LTCF, surgery in the previous 30 days, hospital admission in the previous six months and discharge ward);
- co-morbidities (e.g., diabetes, cancer, renal failure);
- use of devices (central venous catheter CVC, percutaneous endoscopic gastrostomy PEG);
- clinical data (presence of decubitus, chemotherapy or therapy with steroids in the previous 30 days, leucocytosis, on-going antibiotic therapy).

Both microbiological and epidemiological data were collected in a database and statistical analysis was performed using SPSS 12. Variables were compared using chi square test and logistic regression. We accepted p < 0.05 as significant.

Results and discussion

We enrolled all patients with urinary catheter (>24 hours), i.e. 211 patients out of the 2258 who were present in the 23 LTCTFs (Figure 1); 149 patients (70.6%) were in northern Italy, 9 (4.3%) in central Italy and 53 (25.1%) in southern Italy.

Females were 61.6% (130/211), mean age was 83.3 (male 80.4, female 85.2). 68 patients (32.2%) had been in the LTCTF for over 6 months. 26 patients (12.3%) had been hospitalized in the 30 days prior to entering the LTCF. These patients were discharged from the following wards: internal medicine 15 (57.7%), specialist surgery 8 (30.8%), general surgery 2 (7.7%), onco-hematology 1 (3.8%). 29 patients out of 211 (13.7%) had ongoing antibiotic therapy, and 5 of these were administered a multidrug antibiotic therapy. Length of catheterization was ≤1 month for 130

---

![Figure 1](http://www.biomedcentral.com/1471-2334/13/124)  
*Figure 1 Number of individuals present during PPS, with a urinary catheter, with a positive culture and with a BL-producing microorganism.*
Table 2 Number and percentage of BL and ESBL producers

| Specie (n.)          | Isolated microorganisms | Beta lactamases producers | ESBL                      |
|----------------------|-------------------------|---------------------------|--------------------------|
|                      | North n.                | Centre-south n.           | North n. (%)             | Centre-south n. (%)     | North n. (%) | Centre-south n. (%)     |
| Escherichia coli (110) | 76                      | 32                        | 37 (47.4)                 | 9 (26.1)                | 34 (43.6)   | 9 (28.1)                |
| Proteus mirabilis (31) | 30                      | 21                        | 20 (66.7)                 | 18 (65.7)               | 20 (66.7)   | 17 (61.3)               |
| Providencia stuartii (31) | 25                      | 6                         | 17 (68.0)                 | 5 (83.3)                | 16 (64.0)   | 4 (66.7)                |
| Klebsiella pneumoniae (28) | 20                      | 6                         | 7 (35.0)                  | 0 (--)                  | 7 (35.0)    | 0 (--)                  |
| Morganella morganii (27) | 20                      | 3                         | 14 (70.0)                 | 0 (--)                  | 14 (70.0)   | 0 (--)                  |
| Citrobacter koseri (7)   | 7                       | 0                         | 4 (57.1)                  | 0 (--)                  | 4 (57.1)    | 0 (--)                  |
| Enterobacter cloacae (6)   | 2                       | 2                         | 0 (0.0)                   | 1 (50.0)                | 0 (--)      | 0 (--)                  |
| Seneca marcescens (3)     | 3                       | 0                         | 1 (33.3)                  | 0 (--)                  | 0 (--)      | 0 (--)                  |
| Proteus vulgaris (1)       | 1                       | 0                         | 0 (0.0)                   | 0 (--)                  | 0 (--)      | 0 (--)                  |
| Citrobacter freundii (1)  | 1                       | 0                         | 0 (0.0)                   | 0 (--)                  | 0 (--)      | 0 (--)                  |
| Total (257)            | 187                     | 70                        | 100 (53.5)                | 33 (47.1)               | 95 (50.8)   | 30 (42.9)               |

out of 191 patients (68.1%) and >1 month for 61 out of 191 (31.9%).

Thirty-four antibiotics were reported altogether: 44.2% (15/34) were beta-lactams (7 penicillins, 7 cephalosporins and 1 carbapenem), 29.4% (10/34) quinolons, 8.8% (3/34) tetracyclines, 8.8% (3/34) macrolides, 5.9% (2/34) glycopeptides and 2.9% (1/34) trimethoprim-sulfamethoxazole.

56.9% (120/211) of the patients had no reported comorbidities, 24.2% (51/211) had diabetes mellitus, 14.2% (30/211) had renal failure and 12.8% (27/211) had cancer.

A total of 257 microorganisms were isolated from 185 patients; 62.2% (119/185) of urinary samples showed the presence of one single microorganism, 32.4% (60/185) of two bacteria and 3.2% (6/185) of 3 different species.

Phenotypic and molecular tests confirmed a BL-positive result for 133/257 strains (51.8%); 125 strains were ESBL-producers and 7 AmpC hyper producers; one strain was not screened. Double-disc synergy and combo confirmatory tests yielded positive results for all ESBL-producers. AmpC producers were resistant to expanded-spectrum cephalosporins (with the exception of FEP), ATM and cephamycins, while susceptibility to carbapenems was not affected.

114 patients had at least one resistant BL-producer strain. Analytical IEF analysis revealed the presence of at least one BL band with pl5 values ranging from 5.4 to >8.4 in all the above-mentioned isolates (data not shown).

The total number of BL bands and the ability of each enzyme to hydrolyze extended-spectrum cephalosporins (CTX, CAZ, ATM, FEP) and/or FOX, suggested the production - in different strains - of ESBL or of AmpC-type BL (CBL).

In 4 P. mirabilis strains, PCR and sequencing revealed and confirmed the presence of an identical allele in all isolates, which encoded the CMY-16 variant.
Table 3 PCR/sequencing results for each contact centre

| Contact centres (n. of microorganisms) | Strain | N° of strains BL and ESBL patterns |
|---------------------------------------|--------|-----------------------------------|
| CC 1                                  | E. coli (9) | 2 (CTX-M-1, TEM-1), 3 (CTX-M-19, TEM-1), 2 (CTX-M-15, OXA-30, TEM-1), 1 (CTX-M-32, 1 (SHV-2, TEM-1)) |
|                                       | K. pneumoniae (1) | 1 (SHV-1, TEM-15) |
|                                       | P. mirabilis (2) | 1 (TEM-4), 1 (TEM-92 + CMV-16) |
|                                       | M. morganii (1) | 1 (TEM-92) |
|                                       | P. stuartii (6) | 5 (TEM-like), 1 (TEM-60) |

CC 2

| E. coli (5) | 1 (CTX-M-3, TEM-1), 1 (CTX-M-15, OXA-30), 1 (SHV-5, TEM-1), 2 (AmpC, overexpress) |
| K. pneumoniae (1) | 1 (CTX-M-19 + 54, SHV-1) |
| P. mirabilis (2) | 1 (TEM-92, TEM-29), 1 (TEM-92) |
| M. morganii (5) | 5 (TEM-92) |
| P. stuartii (1) | 1 (AmpC) |

CC 3

| E. coli (5) | 2 (CTX-M-15, OXA-1-like), 1 (CTX-M-15, OXA-30, TEM-1), 1 (CTX-M-3, OXA-1-like, TEM-1), 1 (CTX-M-32) |
| K. pneumoniae (3) | 2 (CTX-M-3, SHV-1), 1 (CTX-M-15, SHV-1) |
| P. mirabilis (10) | 8 (TEM-92), 2 (TEM-92 + CMV-16) |
| M. morganii (6) | 6 (TEM-92) |
| P. stuartii (3) | 4 (TEM-like), 1 (TEM-60) |
| C. koseri (4) | 4 (TEM-134, TEM-1) |
| S. marcescens (1) | 1 (AmpC) |

CC 4

| E. coli (18) | 4 (CTX-M-15, OXA-30), 1 (CTX-M-15, OXA-30, TEM-1), 6 (CTX-M-15, TEM-1), 1 (CTX-M-32, TEM-1), 5 (CTX-M-15, OXA-1-like, TEM-1), 1 (AmpC, overexpress) |
| K. pneumoniae (2) | 1 (CTX-M-15, SHV-1), 1 (CTX-M-3, SHV-1) |
| P. mirabilis (6) | 5 (TEM-92), 1 (TEM-4) |
| M. morganii (2) | 2 (TEM-92) |
| P. stuartii (3) | 3 (TEM-like), 2 (TEM-60) |

CC 5

| E. coli (2) | 2 (CTX-M-15, OXA-30, TEM-1) |
| P. mirabilis (1) | 1 (TEM-92 + CMV-16) |

CC 6

| P. mirabilis (1) | 1 (TEM-92) |

The ESBL-positive isolates included 43 E. coli, 37 P. mirabilis, 20 P. vulgaris, 14 M. morganii, 7 K. pneumoniae and 4 C. koseri.

E. coli, P. mirabilis and P. stuartii altogether proved to be the most commonly isolated microorganisms, and P. mirabilis, P. stuartii and M. morganii showed a higher presence of ESBL.

Table 2 summarizes the total number of different species collected in the study, indicating the ones that were positive to ESBL confirmatory tests. There was no statistical significance (chi square test) in prevalence resistance between northern and central-southern Italy LTCFs. Figure 2 shows the percentage of BL-producing strains and ESBL in the different CCs.

E. coli was the most common microorganism detected both in northern areas (CC1, CC2, CC3, CC4) and in central-southern areas (CC5, CC6, CC7, CC8), but while in northern LTCFs it was also the most frequent BL-producer, the most commonly resistant strain in central-southern LTCFs was P. mirabilis. The latter microorganism also showed geographical differences that were statistically significant (OR 1.7 CI 95% 1.06-2.72 p < 0.01), in the expression of TEM-types gene, with TEM-92 present in 90.0% (18/20) of the strains in northern Italy and 52.9% (9/17) of TEM-92 in central-southern Italy where the remaining ones were TEM-4 or TEM-24; Table 3 summarizes the PCR/sequencing results for each contact centre.

Table 4 shows the results of bivariate analysis for patients with the presence of BL-producing microorganisms based on reported characteristics. Also length of catheterization shows no statistically significant differences. In the logistic regression model (Table 4), we included all the variables, and patients with decubitus emerged as those with a statistically significant higher risk of detecting at least one resistant microorganism (OR 3.22 CI 95% 1.57-6.60 p < 0.01). Furthermore, we conducted the same analysis for microorganisms (257) and found that 50 out of 80 (62.5%) microorganisms that
Table 4 General characteristics of studied population and results of bivariate analysis and logistic regression model (211)

| Population characteristics       | n. (% of residents with risk factors) | Bivariate analysis | Logistic regression model |
|----------------------------------|---------------------------------------|-------------------|--------------------------|
|                                 | ESBL/AmpC (-) (n. 97) | ESBL/AmpC (+) (n. 114) | OR CI 95%                 | OR CI 95% | p*     |
| Stay longer than 6 months        | 38 | 30 | 0.56 | 0.31-0.99 | 0.57 | 0.29-0.10 | ns     |
| Hospital admission 30 days before | 17 | 9  | 0.40 | 0.17-0.95 | 0.47 | 0.15-1.44 | ns     |
| Surgery 30 days before           | 5  | 2  | 0.33 | 0.62-1.73 | 0.36 | 0.05-2.75 | ns     |
| Antibiotic therapy               | 13 | 16 | 1.26 | 0.48-3.32 | 1.27 | 0.22-3.08 | ns     |
| Central Venous Catheter          | 3  | 1  | 0.28 | 0.3-2.71  | 0.23 | 0.19-2.46 | ns     |
| Percutaneous Endoscopic Gastrostomy | 8 | 15  | 1.69 | 0.68-4.17 | 1.28 | 0.46-3.57 | ns     |
| Decubitus                        | 21 | 43 | 2.19 | 1.19-4.05 | 3.22 | 1.57-6.60 | p<0.01 |
| Co-morbidities*                  | 44 | 47  | 0.85 | 0.49-1.46 | 0.94 | 0.32-1.69 | ns     |

*Include cancer, diabetes and renal failure.

n = not statistically significant.

came from patients with decubitus were resistant (chi square test OR 1.89 CI 95% 1.10-3.24 and logistic regression OR 2.13 CI 95% 1.14-4.00 p < 0.05); this strengthens the thesis that patients with decubitus are at a higher risk of selecting resistant strains.

Moreover, we found that 18 out of 24 (75%) strains that came from patients undergoing antibiotic therapy showed a high risk of being resistant (chi square test OR 3.08 CI 95% 1.18-8.03 and logistic regression OR 4.70 CI 95% 1.56-14.22 p < 0.01).

This study investigated the circulation of BL-producing *Enterobacteriaceae* in Italian LTCFs. It also analyzed the distribution of the beta-lactam resistant genes throughout the entire national territory and it produced a first nationwide picture of the issue.

We found an overall remarkably high presence of BL-producers 51.8% (133/257), especially of ESBL-producers 48.6% (125/257) in Italian LTCFs, even with variations among centres. We found a high percentage of ESBL circulation particularly for *P. mirabilis* 72.5% (37/51) [24], *P. stuartii* 64.5% (20/31) and *M. morganii* 60.9% (14/23); these data confirm the increase of ESBL-producers in LTCFs reported in other studies [25,26]. Moreover they confirm that CTX-M-type ESBL are the most widespread in *E. coli*, particularly CTX-M-15 [27]; this gene is also the one that was most frequently isolated in acute intensive care hospitals in Italy in other studies [14,28].

Probably, using the CLSI confirmatory test allows to correctly identify the typical ESBL, but it could increase the risk of underestimating the presence of plasmid AmpC-producers. Some authors have already published papers on the spread of CMY-16 *P. mirabilis*, which mainly occurs in northern Italy [21,29].

The aim of the study was to obtain a picture of ESBL circulation in LTCFs. Moreover, in order to better control the existing case mix variability among LTCFs, we selected only patients with a permanent urinary catheter. Nevertheless, the population characteristics are similar to those reported in literature for these patients [5]: prolonged length of stay, high prevalence of co-morbidities, high mean age.

When we explored possible correlations with population variables, we were able to confirm that there is a significant correlation between the presence of decubitus and the presence of at least one beta-lactam resistant microorganism, as was previously reported.

We also found that patients with an ongoing antibiotic therapy had a higher number of expanded-spectrum cephalosporins resistant microorganisms among the isolates, compared to patients without antibiotic therapy. This confirms what is reported in other studies [30].

We selected patients characteristics and clinical risk factors that were compatible with a point prevalence study, but this could have limited the capacity to make clear the role of other factors such as previous use of antibiotic in the population. Relationships with decubitus ulcers must be further explored to be not confounded by other clinical factors that are not included in our model.

Due to the sample dimension and to the patient selection criteria (we limited the study only to patients with urinary catheter), this study certainly cannot be considered as being completely representative of the Italian BL situation, but it does provide a first picture of the problem in the crucial healthcare sector of LTCFs; moreover, it shows the need for urgent investments both in monitoring and controlling antibiotic resistance in LTCFs.

Conclusions

This study confirmed the wide circulation of BL-producing *Enterobacteriaceae* in LTCFs, and particularly the increase of ESBL-producers (CTX-M). This is important to improve effective and appropriate therapeutic choices in LTCFs, where there are fewer opportunities of using microbiological tests and patient conditions (elderly people with many co-morbidities) may easily lead to therapeutic failure. Moreover, since these patients need
to access other healthcare settings quite frequently, this increases the risk of spreading the ESBL among healthcare organizations. Our data confirm a different circulation of expanded-spectrum cephalosporins resistant microorganisms in Italy. This indicates that local monitoring of circulating ESBL-types is relevant and important, since it can provide information about resistance evolution which, in turn, can help make appropriate therapeutic decisions. In healthcare systems, managing LTC is becoming more relevant, and monitoring antibiotic resistances in these settings (including carbapenems, often one of the few remaining therapeutic options) is essential in order to guarantee an appropriate use of antibiotics and high quality of patient care.

Abbreviations
LTCs: Long term care facilities; ESBL: Extended spectrum beta-lactamases; BL: Beta-lactamases; HAs: Healthcare associated infections; LTC: Long term care; CC: Contact centre; PEG: Percutaneous endoscopic gastrostomy; CVC: Central venous catheter; PCR: Polymerase chain reaction.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
BS and RL designed the study. AL performed the statistical analysis, analysed and interpreted data and drafted the manuscript. RL collected data and drafted the manuscript. MS and EN collected all bacterial strains and related data and performed antibiotic susceptibility tests. AA, BI, RA, GR, TS, MA, ZC, PP, PC and PM collected data from LTCs and coordinated CC laboratory work. MS, EN and RM carried out experimental screening work aimed at BL/ESBL detection. RM and EN performed the molecular characterization of the BL/ESBL. RM drafted the manuscript. LP supervised both the BL/ESBL screening work and the genes characteristic activity. RA coordinated microbiological work and drafted the manuscript. PA and VM made phenotypic confirmation. BS coordinated epidemiological work, analysed and interpreted data and drafted the manuscript. The manuscript was revised and approved by all authors.

Request for consent statement
All patients participated in the study on a voluntary basis after signing an informed consent. Patient data were used anonymously. At the time of the study, there was no legal obligation to obtain the approval of an Ethic Committee (DM 15/07/1997 and DM 12/05/2006) prior to conducting an observational (non experimental) studies. At the time of the study the Ethic Committee was mandatory only for experimental studies.

Author details
Department of Medical and Biological Sciences, University of Udine, Udine, Italy.
1Department of Clinical Surgical Diagnostic and Parasitic Sciences, Sect. of Virology, University of Pavia, Pavia, Italy.
2Azienda per i Servizi Sanitari 3 - Alto Friuli, Udine, Italy.
3Virology and Virology, AO Ospedaliero Rumi di Bergamo, Bergamo, Italy.
4University of Cattania, Cattania, Italy.
5University of Bari, Bari, Italy.
6University of Torino, Turin, Italy.
7University of Verona, Verona, Italy.
8Azienda Sanitaria Locale 2 L’ombra Vasto Chieti, Chieti, Italy.
9Azienda provinciale per i servizi sanitari – Provincia autonoma di Trento, Trento, Italy.
10Azienda Sanitaria Locale Taranto, Taranto, Italy.
11Azienda Ospedaliera di Desenzano del Garda, Desenzano del Garda, Italy.

Received: 23 March 2012 Accepted: 26 February 2013

Published: 6 March 2013

References
1. Nicolle LE. Preventing infections in non hospital settings: long term care. Emerg Infect Dis 2001, 7(2):205-207.
2. Nicolle LE, Campbell B, Elmoodi TG, Hierholzer WJ, Jackson MM, Nicolle LE, et al. Definitions of infection for surveillance in long-term care facilities. Am J Infect Control 1991, 19(1):7.
3. Loeb ML, Drenan S, McGeer AJ, Simor AE, Bradley SF, Low DE, et al. Risk factors for resistance to antimicrobial agents among nursing home resident. Am J Epidemiol 2003, 157(1):40-47.
4. Bote G, Armand-Lefèvre L, Llobet I, Guevret W, Delblanc C, Raynal R, et al. Epidemiology of multidrug-resistant bacteria in patients with long hospital stays. Infect Contr Hosp Epidemiol 2007, 28(11):1255-1260.
5. Nicolle LE, Stinus CL, Gallardo PM. Infections and antibiotic resistance in nursing homes. Clin Microbiol Rev 1996, 9(1):1-17.
6. Paterson DL. Resistance in gram-negative bacteria: Enterobacteriaceae. Am J Med 2006, 119(1):20-26.
7. Fang H, Atalee P, Hedin G, Danbouch K. Molecular epidemiology of extended spectrum beta lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2005. J Clin Microbiol 2008, 46(2):707-712.
8. Rodriguez-Baño J, Navarro MD, Romero L, Marmolejo C, Pena E, Perez-Cano S, et al. Clinical and molecular epidemiology of extended spectrum beta lactamases producing Escherichia coli as a cause of nosocomial infection or colonization infections for control. Clin Infect Dis 2006, 42(1):37-45.
9. Nicolau-Chanoine M, Jaunet V, La Collègiale de Bactériologie Virologie Hygiène Hospitalière de Montpellier Publique. Hospital Epidemiology in France: Extended spectrum beta lactamases in long term care facilities. Clin Microbiol Infect 2008, 14(Suppl. 1):111-116.
10. Pena C, Guifflot C, Tubau F, Sabido M, Pujol M, Domínguez MA, et al. Risk factors for acquisition of extended spectrum beta lactamase-producing Escherichia coli among hospitalised patients. Clin Microbiol Infect 2008, 14(2):279-284.
11. Lee YS, Katsafaros S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended spectrum beta lactamases producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006, 27(11):1226-1232.
12. Weiner J, Quinlivan JP, Khalid PA, Gowing R, Nathan C, Buth K, et al. Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999, 281(5):517-523.
13. Turbbiello M, Spata P, Sangiorgi M, Citton R, Montuori E, Locane F, et al. Bloodstream infections caused by extended spectrum beta lactamase producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob Agents Chemother 2006, 50(9):2489-2504.
14. Muzzaiddi C, Luzzaro F, De Luca F, Frigante G, Perilli M, Amicosante G, et al. CTX-M type extended spectrum beta lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 2006, 50(9):2700-2705.
15. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-eighth informational supplement M07-A8. Wayne PA: Clinical and Laboratory Standards Institute; 2008.
16. Nuesch-Andrich R, Achtman M, Hapka H. W. Kohn FH. Detection of genes coding for extended spectrum SHV beta lactamases in clinical isolates by a molecular genetic method and comparison with the E test. Eur J Clin Microbiol Infect Dis 1995, 14(3):284-402.
17. Falchioli L, Malacarza N, Mastrozzi A, Grotti B, Triggis C, Barbioli A, et al. Detection of CTX-M-type beta lactamases genes in fecal Escherichia coli isolates from healthy children in Bolivia and Peru. Antimicrob Agents Chemother 2004, 48(1):453-456.
18. Muzzaiddi C, Luzzaro F, De Luca F, Frigante G, Amicosante G, Rossollini GM. Detection of CTX-M type extended spectrum beta lactamases genes in a hospital strain. J Microbiol 2005, 43(2):1603-1613.
19. Eckert C, Gaurier V, Salle-Allard M, Hidi H, Vedel C, Ouel-Hoelieze B, et al. Detection of CTX-M type beta-lactamases among clinical isolates of Enterobacteriaceae in France. Antimicrob Agents Chemother 2004, 48(4):1249-1255.
20. Stewart CD, Rasher JK, Hubert SK, Biddle AJ, Barnes PA, Anderson GL, et al. Characterization of clinical isolates of Klebsiella pneumoniae from clinical laboratories using the national committee for clinical laboratory standards extended spectrum beta lactamase detection methods. J Clin Microbiol 2001, 39(9):2864-2872.
21. D’Andrea MW, Kuclo E, Luzzano F, Fazio B, Jjakana LV, Viani R, et al. OM-16 a novel acquired Ampc type beta lactamase of the OXMVLAT lineage in mulitfaceted monospecies of Proteus mirabilis from northern Italy. Antimicrob Agents Chemother 2006, 50(6):628-624.
22. Perea-Perea FI, Hanson ND. Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR. J Clin Microbiol 2002; 40(6):2153–2162.
23. Brucafero S, Segattini I, Silvestro A, Vidotto L. Incidence of hospital-acquired infections in Italian long-term-care facilities: a prospective six-month surveillance. J Hosp Infect 2006, 63(2):211–215.
24. Pagani L, Migliavaca R, Palacchi L, Matti M, Giacobone E, Annicostante G, et al. Emerging extended-spectrum beta-lactamases in Proteus mirabilis. J Clin Microbiol 2002, 40(4):1549–1552.
25. Yoo JS, Byeon J, Yang J, Yoo J, Chung GT, Lee YS. High prevalence of extended-spectrum beta-lactamases and plasmid-mediated AmpC beta-lactamases in Enterobacteriaceae isolated from long-term care facilities in Korea. Diagn Microbiol Infect Dis 2010, 67(3):261–265.
26. March A, Aschbacher R, Dhami H, Livermore DM, Böttcher A, Siegel F, et al. Colonization of residents and staff of a long-term care facility and adjacent acute-care hospital geriatric unit by multidrug-resistant bacteria. Clin Microbiol Infect 2010, 16(7):994–998.
27. Urban C, Mariano N, Bradford PA, Tichman MJ, Segal-Maurer S, Weheby W, et al. Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn Microbiol Infect Dis 2010, 66(4):402–406.
28. Casuotti A, Garcia-Fernandez A, Varesi P, Fantini D, Giardini S, Penei A, et al. Molecular epidemiology of Escherichia coli producing extended-spectrum beta-lactamases isolated in Rome, Italy. Clin Microbiol. 2008, 46(1):103–108.
29. Latore P, Brigante G, D’Andrea NM, Pini B, Glisi T, Meitengoli E, et al. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int J Antimicrob Agents 2009, 33(4):328–333.
30. Hawkey PM. The growing burden of antimicrobial resistance. J Antimicrob Chemother 2008, 62(1):x–y.

doi:10.1186/1471-2334-13-124
Cite this article as: Arnoldo et al. Prevalence of urinary colonization by extended-spectrum beta-lactamase Enterobacteriaceae among catheterised inpatients in Italian long-term care facilities. BMC Infectious Diseases 2013 13:124.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit